Literature DB >> 33763244

Frailty impact on postoperative complications and early mortality rates in patients undergoing radical cystectomy for bladder cancer: a systematic review.

Paola I Ornaghi1,2, Luca Afferi1, Alessandro Antonelli2, Maria A Cerruto2, Livio Mordasini1, Agostino Mattei1, Philipp Baumeister1, Giancarlo Marra3, Wojciech Krajewski4, Andrea Mari5, Francesco Soria3, Benjamin Pradere6, Evanguelos Xylinas7, Alessandro Tafuri2, Marco Moschini1.   

Abstract

Objective: To assess the prevalence of frailty, a status of vulnerability to stressors leading to adverse health events, in bladder cancer patients undergoing radical cystectomy (RC), and test the impact of frailty measurements on postoperative adverse outcomes.
Methods: A systematic review of English-language articles published up to April 2020 was performed. Electronic databases were searched to quantify the frailty prevalence in RC patients and assess the predictive ability of frailty indexes on RC-related outcomes as postoperative complications, early mortality, hospitalization length (LOS), costs, discharge dispositions, readmission rate.
Results: Eleven studies were selected. Patients' frailty was identified by Johns Hopkins indicator (JHI) in two studies, 11-item modified Frailty Index (mFI) in four, 5-item simplified FI (sFI) in three, 15-point mFI in one, Fried Frailty Criteria in one. Considering all the frailty measurements applied, 8% and 31% of patients were frail or pre-frail, respectively. Frail (43%) and pre-frail patients (35%) were more at risk of major complications compared to non-frail (27%) using sFI; with JHI the percentages of frail and non-frail were 53% versus 19%. According to JHI and mFI frailty was related to longer LOS and higher costs. JHI identified that 3% of frail patients experience in-hospital mortality versus 1.5% of non-frail. Finally, using sFI, frail (28%), and pre-frail (19%) were more likely to be discharged non-home compared to non-frail patients (8%) and had a higher risk of 30-day mortality (4% and 2% versus 1%). Conclusions: Almost half of RC patients were frail or pre-frail, conditions significantly related to an increased risk of postoperative adverse events with higher rates of major complications and early mortality. The most-used frailty index was mFI, while JHI and sFI resulted the most reliable to predict early postoperative RC-related adverse outcomes and should be routinely included in clinical practice after better standardization throughout prospective comparative studies. Abbreviations: ACG: Adjusted Clinical Groups; ACS: American College Surgeons; AUC: area under the curve; BCa: bladder cancer; CCI: Charlson Comorbidity Index; CSHA-FI: Canadian Study of Health and Aging Frailty Index; CCS: Clavien-Dindo Classification Score; ERAS: Enhanced Recovery After Surgery; FFC: Fried Frailty Criteria; (e)(m)(s)FI: (extended) (modified) (simplified) Frailty Index; ICU: intensive care unit; IQR: interquartile range; (p)LOS: (prolonged) length of hospital stay; NSQIP: National Surgical Quality Improvement Program; OR: odds ratio; (O)PN: (open) partial nephrectomy; PRISMA: Preferred Reporting Items for Systematic reviews and Meta-Analyses; (O)(RA)RC: (open)(robot-assisted) radical cystectomy; (O)RN: (open) radical nephrectomy; ROC: receiver operating characteristic; RNU: radical nephroureterectomy; (R)RP: (retropubic) radical prostatectomy; RR: relative risk; THCs: total hospital charges; nephrectomy; UD: urinary diversion.
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Entities:  

Keywords:  Bladder cancer; complications; cystectomy; frailty; mortality

Year:  2020        PMID: 33763244      PMCID: PMC7954492          DOI: 10.1080/2090598X.2020.1841538

Source DB:  PubMed          Journal:  Arab J Urol        ISSN: 2090-598X


  43 in total

Review 1.  Frailty as a prognostic indicator in the radical cystectomy population: a review.

Authors:  Niki Parikh; Pranav Sharma
Journal:  Int Urol Nephrol       Date:  2019-06-07       Impact factor: 2.370

2.  Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes.

Authors:  Mohammad Abufaraj; Beat Foerster; Eva Schernhammer; Marco Moschini; Shoji Kimura; Melanie R Hassler; Mark A Preston; Pierre I Karakiewicz; Mesut Remzi; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2018-12-13       Impact factor: 20.096

3.  Frailty as a predictor of complications after radical cystectomy: A prospective study of various preoperative assessments.

Authors:  Madeleine L Burg; Thomas G Clifford; Soroush T Bazargani; Michael Lin-Brande; Gus Miranda; Jie Cai; Anne K Schuckman; Hooman Djaladat; Siamak Daneshmand
Journal:  Urol Oncol       Date:  2018-11-15       Impact factor: 3.498

4.  Impact of frailty on complications in patients undergoing common urological procedures: a study from the American College of Surgeons National Surgical Quality Improvement database.

Authors:  Anne M Suskind; Louise C Walter; Chengshi Jin; John Boscardin; Saunak Sen; Matthew R Cooperberg; Emily Finlayson
Journal:  BJU Int       Date:  2016-01-17       Impact factor: 5.588

5.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

Review 6.  Frailty and perioperative outcomes: a narrative review.

Authors:  Thomas Beggs; Aresh Sepehri; Andrea Szwajcer; Navdeep Tangri; Rakesh C Arora
Journal:  Can J Anaesth       Date:  2014-11-25       Impact factor: 5.063

Review 7.  Critical Review of Outcomes from Radical Cystectomy: Can Complications from Radical Cystectomy Be Reduced by Surgical Volume and Robotic Surgery?

Authors:  Marco Moschini; Giuseppe Simone; Arnulf Stenzl; Inderbir S Gill; James Catto
Journal:  Eur Urol Focus       Date:  2016-03-17

Review 8.  Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature.

Authors:  Andrea Mari; Riccardo Campi; Riccardo Tellini; Giorgio Gandaglia; Simone Albisinni; Mohammad Abufaraj; Georgios Hatzichristodoulou; Francesco Montorsi; Roland van Velthoven; Marco Carini; Andrea Minervini; Shahrokh F Shariat
Journal:  World J Urol       Date:  2017-11-16       Impact factor: 4.226

Review 9.  Trends in quality of life reporting for radical cystectomy and urinary diversion over the last four decades: A systematic review of the literature.

Authors:  Karan Rangarajan; Bhaskar K Somani
Journal:  Arab J Urol       Date:  2019-04-14

Review 10.  Robot-assisted radical cystectomy with intracorporeal urinary diversion - The new 'gold standard'? Evidence from a systematic review.

Authors:  Niyati Lobo; Ramesh Thurairaja; Rajesh Nair; Prokar Dasgupta; Muhammad Shamim Khan
Journal:  Arab J Urol       Date:  2018-04-11
View more
  4 in total

1.  Novel Antimicrobial Strategies to Prevent Biofilm Infections in Catheters after Radical Cystectomy: A Pilot Study.

Authors:  Rosa Gaglione; Katia Pane; Maria De Luca; Monica Franzese; Angela Arciello; Francesco Trama; Stefano Brancorsini; Marco Salvatore; Ester Illiano; Elisabetta Costantini
Journal:  Life (Basel)       Date:  2022-05-27

2.  Impact of preoperative laboratory frailty index on mortality and clinical outcomes in older surgical patients with cancer.

Authors:  Yoonjoo Kim; Kijun Song; Chang Moo Kang; Hyangkyu Lee
Journal:  Sci Rep       Date:  2022-06-02       Impact factor: 4.996

Review 3.  Framework, component, and implementation of enhanced recovery pathways.

Authors:  Chao-Ying Kowa; Zhaosheng Jin; Tong J Gan
Journal:  J Anesth       Date:  2022-07-05       Impact factor: 2.931

4.  Outcomes of radical cystectomy in pT4 bladder cancer frail patients: Α high-volume single center study.

Authors:  Panagiotis Velissarios Stamatakos; Dimitrios Moschotzopoulos; Ioannis Glykas; Charalampos Fragkoulis; Nikolaos Kostakopoulos; Georgios Papadopoulos; Georgios Stathouros; Odysseas Aristas; Athanasios Dellis; Athanasios Papatsoris; Konstantinos Ntoumas
Journal:  J Frailty Sarcopenia Falls       Date:  2022-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.